KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Assets (2019 - 2022)

Esperion Therapeutics (ESPR) has disclosed Other Non-Current Assets for 4 consecutive years, with $50.0 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Other Non-Current Assets changed 0.0% year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Sep 2022, changed 0.0%, and an annual FY2021 reading of $50.0 million, changed N/A over the prior year.
  • Other Non-Current Assets was $50.0 million for Q3 2022 at Esperion Therapeutics, roughly flat from $50.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $50.0 million in Q3 2021 and bottomed at $928000.0 in Q2 2019.
  • Average Other Non-Current Assets over 4 years is $23.3 million, with a median of $1.3 million recorded in 2020.
  • Peak annual rise in Other Non-Current Assets hit 39.44% in 2020, while the deepest fall reached 22.21% in 2020.
  • Year by year, Other Non-Current Assets stood at $928000.0 in 2019, then soared by 39.44% to $1.3 million in 2020, then surged by 3763.99% to $50.0 million in 2021, then changed by 0.0% to $50.0 million in 2022.
  • Business Quant data shows Other Non-Current Assets for ESPR at $50.0 million in Q3 2022, $50.0 million in Q2 2022, and $50.0 million in Q1 2022.